The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines for the management of chronic kidney disease (CKD) includes a class 1A recommendation for the use of SGLT2 inhibitors in patients with type 2 diabetes, CKD and an estimated glomerular filtration rate (eGFR) >20 ml/min/1.73 m2 [10]. Here, SLC5A2 is linked to chronic kidney disease.